(Q44565526)

4 December 2017

Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study (English)

1 reference

4 December 2017

Suong Tran

1

1 reference

4 December 2017

Roderick S Hooker

series ordinal

2

1 reference

4 December 2017

Daisha J Cipher

series ordinal

3

1 reference

4 December 2017

Andreas Reimold

series ordinal

4

1 reference

4 December 2017

1 January 2009

1 reference

4 December 2017

1 reference

4 December 2017

26

1 reference

4 December 2017

7

1 reference

4 December 2017

607-615

1 reference

https://scigraph.springernature.com/pub.10.2165/11316350-000000000-00000

4 December 2017

0 references

cites work

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

1 reference

12 December 2020

Infliximab for psoriasis and psoriatic arthritis

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period

1 reference

12 December 2020

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

1 reference

12 December 2020

Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients

1 reference

12 December 2020

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

12 December 2020

Early rheumatoid arthritis patients: relationship of age

1 reference

12 December 2020

Long term safety of etanercept in elderly subjects with rheumatic diseases

1 reference

12 December 2020

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

1 reference

12 December 2020

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

12 December 2020

Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification.

1 reference

12 December 2020

Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis

1 reference

12 December 2020

Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis?

1 reference

12 December 2020

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

12 December 2020

Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

1 reference

12 December 2020

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

12 December 2020

Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides

1 reference

12 December 2020

Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients

1 reference

12 December 2020

Rheumatoid arthritis in the elderly: is it a different disease?

1 reference

12 December 2020

Severe pyogenic infections in patients taking infliximab: a regional cohort study

1 reference

12 December 2020

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

12 December 2020

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

1 reference

12 December 2020

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

12 December 2020

Treatment of inflammatory bowel disease in the elderly: an update

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results.

1 reference

12 December 2020

Treatment of inflammatory bowel disease: a review of medical therapy

1 reference

12 December 2020

Survival and safety of treatment with infliximab in the elderly population

1 reference

12 December 2020

Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha

1 reference

12 December 2020

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

12 December 2020

Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.

1 reference

12 December 2020

10.2165/11316350-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

4 December 2017

0 references

1 reference